1Koprowski H, Herlyn M, Selplewski Z, et al. Colorectai Carcinoma antigens detected by hybridoma anti- bodies,Somat Cell Genet 1979;5:957.
2Sperti C, Pasquali C, Guolo PM et al. Serum tumor markers and cyst fluid analysis are useful for the diag- nosis of pancreatic cystic tumors. Cancer, 1996, pancreatic cystic tumors. Cancer, 1996,78 (2) :237.
3Pana A. Intestinai neuronal dysplasia. Myth or reality literature review. Pediatr Surg Int. 1995,10:441.
4Willett CC, Daly WJ, Warshaw AL et al, CM9 -9 is an index of response to neoadjunctive che moradiation therapy in pancreatic cacer, Am J surg, 1996, 172 (4) :350.
3[1]Markus A, Rorhlin, Joller H, et al. CA242 is a new tumor marker for pancreatic cancer[J]. Cancer, 1996, 71(2):701.
4[2]Ventrucci M, Ubalducci GM, Cipolla A, et al. Serum CA242:The search for a valid marker of pancreatic cancer[J]. Clin chem.Lab Med, 1998, 36(3):179.
5[3]Haglund C, Lundin J, Kuusela P, et al.CA242, a new tumor marker for pancreatic cancer: a comparison with CA19-9, CA50 and CEA[J]. Br J Cancer, 1994, 70(3):487.
6[4]Lundin J, Roberts PJ, Kuusela P. Prognostic significance of serum CA242 in pancreatic cancer. A comparison with CA19-0[J]. Anticancer Res, 1995, 15(5B):2181.
7[5]Montgomery RC, Hoffiman JP, Riley LB, et al. Prediction of recurrence and survival by postresection CA19-9 values in patients with adenocarcinoma of the pancreas[J]. Ann Surg Oncol, 1997, 4(7):551.
8[6]Capelli G, Paladini S, D'Agata A, et al. Tumor markers in the diagnosis of pancreatic cancer[J]. Tumori, 1999,85(1, Supp1.1):S19.
10Dr. Richard C. Montgomery MD,John P. Hoffman MD,Lee B. Riley MD, PhD,Andre Rogatko PhD,John A. Ridge MD, PhD,Burton L. Eisenberg MD. Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas[J] 1997,Annals of Surgical Oncology(7):551～556
